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Introduction. Chronic infections and infestations represent one 
of the leading causes of cancer.  Eleven agents have been catego-
rized by the International Agency for Research on Cancer (IARC) 
in Group 1, 3 in Group 2A and 4 in Group 2B.  We previously 
estimated that the incidence of cancers associated with infectious 
agents accounted for the 8.5% of new cancer cases diagnosed in 
Italy in 2014. 
Methods. In the present study we evaluated the incidence of can-
cer in Italy and in the 20 Italian regions in 2018, based on the data 
of Cancer Registries, and calculated the fraction attributable to 
infectious agents.
Results. Cancers of infectious origin contributed to the overall 
burden of cancer in Italy with more than 27,000 yearly cases, the 
92% of which was attributable to Helicobacter pylori, human 
papillomaviruses, and hepatitis B and C viruses. With the excep-
tion of papillomavirus-related cancers, the incidence of cancers 
of infectious origin was higher in males (16,000 cases) than in 
females (11,000 cases). There were regional and geographical 
variations of cancers depending on the type of cancer and on the 
gender. Nevertheless, the overall figures were rather similar, the 
infection-related cancers accounting for the 7.2, 7.6, and 7.1% of 
all cancers in Northern, Central, and Southern Italy, respectively. 
Conclusions. The estimate of the incidence of cancers attributa-
ble to infectious agents in Italy in 2018 (7.3% of all cancer cases) 
is approximately half of the worldwide burden, which has been 
estimated by IARC to be the 15.4% of all cancer cases in 2012.
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Introduction
Altogether, chronic infections and infestations represent 
one of the leading causes of cancer worldwide. Eleven 
agents have been categorized by IARC (International 
Agency for Research on Cancer) in Group 1 (sufficient 
evidence of carcinogenicity to humans), 3 in Group 2A 
(probably carcinogenic), and 4 in Group 2B (possibly 
carcinogenic) [1]. Several other viruses, bacteria and 
protozoa have been suspected to be associated with vari-
ous human cancers [2, 3]. 
The global burden of infection-related cancers has been 
estimated and periodically updated at IARC. The popula-
tion attributable fraction (PAF) in the world population, 
in terms of incidence, was estimated to be the 15.6% 
in 1990 [4], 17.8% in 2002 [5], 16.1% in 2008 [6], and 
15.4% in 2012 [7]. The last figure corresponds to 2 mil-
lion new cancer cases of infectious origin out of 14 mil-
lion cases of all cancers, with broad variations depend-
ing on the geographical region and on the developmen-
tal status. In fact, the PAFs varied from less than 5% in 
North America, Australia-New Zealand and some West-
ern and Northern Europe countries to more than 50% in 
sub-Saharian Africa countries [7].
The PAF, indicating the proportion of cancers of infec-
tious and parasitic origin, has been estimated in various 
countries based either on morbidity and/or on mortal-
ity data. Thus, mortality PAF estimates have been 
made in the USA in 1981  (10%) [8], in the UK both 
in 1998 (10-20%) [9] and 2005 (5%) [10], in France in 
2000 (3.6%) [11], and in China in 2005 (29.4%) [12]. 
Other studies estimated incidence data or both inci-
dence and mortality data. For instance, the 4.1% of all 
new cancer cases occurring in France in 2015 were at-
tributable to infectious agents [13]. In China, infection-
related cancers accounted in 2005 for 25.9 and 29.4% 
of the overall cancer cases and deaths, respectively [14]. 
In another study in China, cancers related to the main 
cancer-related pathogens in men and women account-
ed for 17.7 and 15.4% (incidence) and 20.0 and 16.9% 
(mortality), respectively [15]. In the Korean population, 
for 2007 the fractions of all cancers attributable to infec-
tion were 25.1% and 16.8% for cancer incidence in men 
and women, and 25.8% and 22.7% for cancer mortality 
in men and women, respectively [16]. The 2.9% of can-
cers diagnosed in Australia in 2010 were attributable to 
infectious agents [17].
We previously estimated the PAF of infection-relat-
ed cancers in Italy, based on 2014 national incidence 
data  [2]. That analysis demonstrated that cancers as-
sociated with 6 pathogens accounted for 31,000 out of 
365,000 new yearly cases (8.5%), 42.0% of which was 
S. DE FLORA ET AL.
E312
attributable to Helicobacter pylori (Hp), 34.7% to hepa-
titis B virus (HBV) and hepatitis C virus (HCV), 19.8% 
to human papillomaviruses (HPV), 2.9% to human her-
pesvirus 8 (HHV8) or Kaposi’s sarcoma virus (KSHV), 
and 0.2% to human herpesvirus 4 (HHV4) or Epstein-
Barr virus (EBV). The objectives of the present study 
were to reassess the incidence of infection-related can-
cers in Italy 4 years later and to evaluate the geographi-
cal distribution of these cancers in the 20 Italian regions. 
To this purpose, we made estimates of the incidence and 
of the attributable fractions (AFs) of cancers associated 
with IARC Group 1 pathogens, excepting the infesta-
tions by trematodes, which are rare in Italy, and HIV-1 
infections, because HIV-related immunodeficiency re-
quires the concomitant infection with other carcinogenic 
infectious agents [1].
Methods
Monitored regions and coverage by cancer 
registries (CR)
The study covered the whole Italian territory, which in-
cludes 20 regions whose localization is shown in the map 
(Fig. S1). The regions were grouped according to geo-
graphic areas (North, Central or South) [18]. Northern 
regions include, in alphabetical order, Emilia Romag-
na, Friuli Venezia Giulia, Liguria (Ligury), Lombardia 
(Lombardy), Piemonte (Piedmont), Trentino Alto Adige 
(Trentino South-Tyrol), Valle d’Aosta (Aosta Valley), 
and Veneto, having an overall population of 27,746,158 
residents as to January 2018 (Tab. SI). Central regions 
include Lazio (Latium), Marche (Marches), Toscana 
(Tuscany), and Umbria, having an overall population 
of 12,050,054 residents (Tab. SII). Southern and Insular 
regions include Abruzzo, Basilicata, Calabria, Molise, 
Puglia (Apulia), Sardegna (Sardinia), and Sicilia (Sici-
ly), having an overall population of 20,697,761 residents 
(Tab. SIII).
The estimate of the incidence of cancers associated with 
chronic infections in the male and female population of 
whole Italy and of individual regions was based on the 
data available from Italian CRs, which in 2018 covered 
the 68% of the national population. In particular, the 
coverage in Northern regions was on an average 71% 
(Tab. SI), the coverage in Central regions was 25% (Tab. 
SII), and the coverage in Southern and Insular regions 
was 65% (Tab. SIII). 
Estimates of the incidence of cancers of 
infectious origin
The evaluated agents covered DNA viruses, including 
HPV, HHV4/EBV, HHV8/KSHV, and HBV, either alone 
or in coinfection/superinfection with hepatitis D virus 
(HDV); RNA viruses, including HCV and human T-
lymphotropic virus-I (HTLV-I); and bacteria, including 
Hp. The main cancers associated with the above patho-
gens are shown in Tables SI-SIII. The incidence esti-
mates were selected from the AIOM-AIRTUM publica-
tion [19] for the available cancer sites (oropharynx, liver, 
uterine cervix, vulva, vagina, penis, Hodgkin’s lympho-
ma, Kaposi’s sarcoma). The remaining sites (non-cardia 
stomach, MALT, oral cavity, larynx, nasopharynx, Bur-
kitt’s lymphoma, adult T cell lymphoma/leukemia) were 
estimated by applying the previously described method-
ology [19], that is: a) preliminary time trend analysis; 
b) computation of regional incidence rates (with correc-
tion for incomplete coverage when necessary); c) pro-
jection of incidence rates to 2018; and d) application of 
rates to the resident population. A preliminary time trend 
analysis was made by selecting data from CRs with com-
plete information on incidence during the 2003-2014 pe-
riod. Cancer sites, three major age group (0-49, 50-69, 
70+ years) and sex were considered. The average annual 
percent change (APC) of age-standardized incidence 
rates was estimate by a Joinpoint analysis [20]. APCs for 
the most recent period were considered for projections.
Regional incidence rates
Site-, sex-, age- and region-specific rates were comput-
ed in the calendar period 2010-14 (observed rate). Also 
site-, sex-, age- and geographic area- specific rates were 
computed for the same calendar period. Then regional 
rates were obtained as the weighted average between the 
observed rate and the area specific rates: Regional rate = 
α*Observed rate + (1-α)*Area specific rate, where α is 
the regional coverage. Consequently, in case the propor-
tion of population covered by CRs is 0%, as it was the 
case for 3 regions (Marche, Abruzzo, and Molise), the 
regional rate equals the area specific rate, in case such a 
proportion is 100% the regional rate equals the observed 
rate. In Lazio and Campania the average rate was com-
puted between observed rates and national pool data, in-
stead of area specific ones.
Projection of incidence rates to 2018 
and application of rates to the resident 
population
We assumed that incidence observed in the period 2010-
2014 represent on an average the incidence of the year 
2012 and that the time trend observed in the most recent 
time interval between 2003 and 2014 does not vary dur-
ing the subsequent six years. Moreover, in order to take 
into account the random variability, when the site-, sex- 
and age- trend variation was not statistically significant 
(that is 95% confidence intervals include 0), the APC 
was constrained to 1. Therefore, incidence rates were 
projected to 2018 by multiplying the site-, sex-, age- and 
region- specific rates. The site-, sex-, age- and region- 
specific projected rates were multiplied by the region 
and age specific resident population in 2018, based on 
prevision from the National Statistical Institute [21].
Attributable fractions
The fraction of each cancer attributable to infectious 
agents was inferred from data available in the literature. 
In particular, as detailed in Table I, the data for HBV (± 
HDV) + HCV-related liver cancer made reference to the 
Italian population [22]. The data for HPV-related oro-
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Tab. I. Estimates of total incident cancer cases and of incident cancer cases attributable to the main cancer-associated infectious agents in 
Italy in 2014 and 2018.
 Italy, 2014 [2] Italy, 2018 [present study]
Cancer site
(ICD-10)
Infectious
agent
AF Gender Total
incident
cases
Infection-
related
cases
AF Gender Total
incident
cases
Infection-
related
cases
Non-cardia 
stomach 
(C16.1-C16.9)
Hp
0.90
(World [6])
M
F
M+F
7,500
5,500
13,000
6,750
4,950
11,700
0.89
(World [7])
M
F
M+F
8,156
5,060
13,216
7,259
4,503
11,762
MALT
(C88.4) Hp
0.86
(World [6])
M
F
M+F
700
850
1,550
602
731
1,333
0.74
(World [7])
M
F
M+F
169
112
281
125
83
208
Total Hp-
associated 
cancers
Hp
M
F
M+F
8,200
6,350
14,550
7,352
5,681
13,033
M
F
M+F
8,325
5,172
13,497
7,384
4,586
11,970
Liver
(C22)
HBV
(± HDV)
+HCV
0.87
(Italy [29])
M
F
M+F
8,600
3,800
12,400
7,465
3,298
10,763
0.68
(Italy [22])
M
F
M+F
8,929
3,966
12,895
6,071
2,697
8,768
Uterine cervix
(C53)
HPV
1.00
(World [6])
F 2,200 2,200
1.00
(World [23])
F 2,241 2,241
Vulva
(C51)
HPV
0.40
(World [24])
F 900 364
0.25
(World [24])
F 1,266 317
Vagina
(C52)
HPV
0.61
(World [24])
F 200 122
0.78
(World [23])
F 226 176
Penis
(C60)
HPV
0.47
(World [24])
M 182 85
0.50
(World [23])
M 563 282
Oral cavity
(C00-C08)
HPV
0.24
(World [25])
M
F
M+F
2,283
1,524
3,807
537
358
895
0.04
(World [7])
M
F
M+F
3,034
1,721
4,755
121
69
190
Oropharynx
(C09-C10, 
C12-C14)
HPV
0.36
(World [25])
M
F
M+F
1,214
348
1,562
432
124
566
0.24
(South 
Europe [7])
M
F
M+F
1,552
407
1,959
372
98
470
Larynx
(C32)
HPV
0.24
(World [25])
M
F
M+F
3,714
335
4,049
891
80
971
0.05
(World [7])
M
F
M+F
4,076
500
4,576
204
25
229
Total HPV-
associated 
cancers
HPV
M
F
M+F
7,393
5,507
12,900
1,945
3,248
5,203
M
F
M+F
9,225
6,561
15,786
979
3,126
4,105
Nasopharynx
(C11)
EBV (HHV4)
0.80 (Low
incidence 
regions [6])
M
F
M+F
315
124
439
252
99
351
0.80
(Low 
incidence 
regions [7])
M
F
M+F
452
156
608
362
125
487
Burkitt’s 
lymphoma
(C83.7)
EBV (HHV4) 
±
Pf
0.20
(USA & 
Europe [6])
M
F
M+F
200
100
300
40
20
60
0.20
(USA & 
Europe [6])
M
F
M+F
115
44
159
23
9
32
Hodgkin’s 
lymphoma
(C81)
EBV (HHV4) NA NA
0.36 
(Europe 
[7])
M
F
M+F
1,228
1,013
2,241
442
365
807
Total EBV-
associated 
cancers
EBV (HHV4)
M
F
M+F
515
224
739
292
119
411
M
F
M+F
1,795
1,213
3,008
839
503
1,342
Kaposi’s 
sarcoma
(C46)
KSHV 
(HHV8)
1.00
(World [6])
M
F
M+F
600
300
900
600
300
900
1.00
(World [23])
M
F
M+F
646
280
926
646
280
926
Adult T cell 
lymphoma/
leukemia 
(C91.5)
HTLV1 NA NA
1.00
(World [23])
M 
F
M+F
12
2
14
12
2
14
All the above 
cancers
M
F
M+F
25,758
16,831
42,589
18,034
13,194
31,238
M
F
M+F
28,932
17,194
46,126
15,894
11,178
27,072
Hp: Helicobacter pylori; HBV: hepatitis B virus; HCV: hepatitis C virus; HDV: hepatitis D virus (Delta agent); HPV: human papillomavirus; EBV: Epstein-Barr 
virus; HHV4: human herpesvirus 4; PF: Plasmodium falciparum; KSKV: Kaposi’s sarcoma virus; HHV8: human herpesvirus 8; HTLV: human T-lymphotropic 
virus; AF: attributable fraction; M: males; F: females.; NA: not available.
S. DE FLORA ET AL.
E314
pharynx cancer were related to the South Europe popu-
lation and those for EBV-related Hodgkin’s lymphoma 
were related to the European population [7]. Those re-
lated to Burkitt’s lymphoma were related to the USA 
and European populations [6]. All the other cancers 
were related to the world population [6, 7, 23-25]. As 
shown in Table I, the AFs for individual cancers ranged 
from a minimum of 0.04 for HPV-related oral cancer 
to a maximum of 1 for KSHV/HHV8-related Kaposi’s 
sarcoma, HTLV-1-related adult T cell lymphoma/leuke-
mia, and HPV-related uterine cervix cancer. However, it 
is known that lifestyle, environmental and genetic fac-
tors can affect the susceptibility to HPV-related cervical 
cancer [26].
Results
Comparison of the incidence of infection-
related cancers in Italy in 2014 and 2018
Table I compares the incidence of infection-related can-
cers in Italy as estimated in 2014 [2] with the one esti-
mated in 2018 (present study). According to the more re-
cent estimate, there was a 13% decrease in the incidence 
of all cancers associated with chronic infections, which 
accounted for a total of 31,238 cases in 2014 and a total 
of 27,072 cases in 2018. Such a decrease depends both 
on methodological issues and on variations in the AFs 
adopted during that period. In particular, in the case of 
Hp-related cancers the incidence of non-cardia stomach 
was very similar in 2014 and 2018. In contrast, there was 
a sharp drop in Hp-related MALT cases especially be-
cause of a different methodological approach. As to the 
liver cancers attributable to HBV and HCV, the 1.23-fold 
decrease in the incidence from 2014 to 2018 parallels a 
1.28-fold decrease in the adopted AFs. The estimates of 
HPV-related cancers of female genitals were very simi-
lar in 2014 and 2018. In contrast, there was an apparent 
increase in HPV-related penis cancer in 2018 because 
of a different methodological approach. The estimate of 
the incidence of HPV-related cancers of the upper aer-
odigestive tract was much lower in 2018 because in the 
meantime a considerable drop of the AFs had been pro-
posed. Some variations also occurred for EBV-related 
cancers because Hodgkin’s lymphoma had not been in-
cluded in 2014. The estimate of KSHV (HHV8)-relat-
ed Kaposi’s sarcoma was almost identical in 2014 and 
2018, whereas very few cases of HTLV1-related adult T 
cell lymphoma/leukemia had not been computed in the 
previous study.
Incidence of infection-related cancers in the 
italian regions in 2018
Tables SI, SII and SIII report the resident male and 
female population in 2018 [27], the percentage of the 
population covered by accredited CRs, and the esti-
mated incidence of cancers, expressed as cases/100,000 
residents, attributable to infectious agents in Northern, 
Central and Southern Italian regions, respectively. The 
panels in Figure 1 display maps that show the estimated 
incidence of cancers of infectious origin in the male and 
female population of the 20 Italian regions in 2018. As 
to all cancers of infectious origin (Fig. 1A), there was 
an evident intergender difference, which among males 
was characterized by a general trend to a gradient from 
North to South, with a maximum of 67 cases/100,000 
in Veneto and a minimum of 39 cases/100,000 in Sic-
ily. A similar picture was apparent in the female popu-
lation, but with some regional exceptions. In fact, the 
maximum incidence was in Umbria (42 cases/100,000) 
but with close data in a Southern region (Basilicata). On 
the whole, by combining the two genders, the total num-
ber of cases/100,000 residents in Northern, Central and 
Southern regions were 94.4, 97.2 and 85.6, respectively.
A strong difference between males and females was also 
evident for HBV/HCV-related liver cancer (Fig. 1B), 
with sharp interregional variations in the male popula-
tion, where the maximum incidence values were record-
ed in Northwestern regions, while a more homogeneous 
regional distribution occurred in the female population. 
By combining the two genders, the number of HBV/
HCV-related liver cancer cases/100,000 residents in 
Northern, Central and Southern regions were 31.2, 24.4 
and 30.3, respectively. 
The higher incidence of all HPV-related cancers in fe-
males, compared to males, is evident from the values 
reported in Fig. 1C. The interregional differences were 
not sharp, although there was a regular gradient from 
North to South, especially in the female population. By 
combining the two genders, the number of HPV- related 
cancer cases/100,000 residents in Northern, Central and 
Southern regions were 15.2, 13.8 and 11.9, respectively.
The incidence of Hp-related cancers was considerably 
higher in males than in females (Fig. 1D). The highest 
incidence values were clustered in Central Italy regions. 
By combining the two genders, the number of Hp-re-
lated liver cancer cases/100,000 residents in Northern, 
Central and Southern regions were 42.0, 52.9 and 34.3, 
respectively.
Table SIV reports the estimates of total incident cancer 
cases for the whole Italy and by region and area. By cu-
mulating the two genders, the infection-related cancers 
in Northern, Central, and Southern Italy accounted in 
2018 for the 7.2, 7.6, and 7.1% of all cancers, respec-
tively. The national figure was 7.3%, corresponding to 
27,381 cases of infection-related cancers out of a total of 
373,300 incident cases.
Discussion
The present study estimated the incidence of the most 
relevant cancers associated with chronic infections over 
the whole national territory and, individually, in the 20 
Italian regions. Drawing an up-to-date picture of the 
epidemiological situation is important because of the 
evolving estimates of PAFs and of our knowledge about 
the infectious origin of cancer. For instance, Hp role in 
gastric cancer was established in the nineties, the role 
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of HPV in head and neck cancer has recently been as-
sessed, and recent studies are suggesting a role for other 
pathogens, such as the involvement of EBV in gastric 
cancer development, either alone or in coinfection with 
Hp [28]. 
The overall national estimates of infection-related can-
cers in 2018 (present study) were slightly lower than 
those made in 2014 [2], with a decrease from a total 
of 31,238 new cases to 27,072 cases (-13%). For some 
cancers, such as Hp-related non-cardia stomach cancer, 
HPV-related uterine cervix cancer and KSHV-related 
Kaposi’s sarcoma, the estimates were virtually overlap-
ping in 2014 and 2018. For other cancers there were 
variations, mainly in the sense of a decrease, which de-
pended either on technical issues or on the lower AFs 
adopted recently. 
The most paradigmatic example of AF resizing is pro-
vided by liver cancer attributable to hepatotropic viruses. 
In the previous study, we adopted an AF of 0.87, which 
was based on an estimate made in Italy in 2001 [29]. Al-
ready at that time, HCV infections overwhelmed HBV 
infections in the causation of primary hepatocellular car-
cinoma in Italy [29]. Later on, the scenario has further 
evolved, with a progressively increasing contribution of 
non-viral factors and a decrease of the role of the viral 
etiology, which went down to 67.6% in the quinquen-
nium 2010-2014, with the contribution of 8.6% by HBV 
(± HDV), 47.3% by HCV, 1.5% by HBV + HCV, and 
10.5% classified as multi-etiology [22]. Indeed, as in-
ferred from 770,000 cases of liver cancer occurring 
worldwide in 2012, the contribution of these hepatotrop-
ic viruses to liver cancer is sharply variable according to 
the geographical area, HBV causing approximately 2 of 
3 liver cancers in developing countries but 1 in 4 cases 
in more developed countries [30]. Such a trend appears 
to be even more pronounced in Italy. Screening for HBV 
and HCV was introduced to reduce transmission among 
high risk groups. HCV screening has gained increasing 
diffusion because of the potential of antiviral drugs to 
eliminate the infection, which led WHO to pose the ob-
jective of eradication in 2030 [31].
Hp, HPV, HBV and HCV together accounted for the 
92% of all infection-attributable cancers diagnosed both 
in the world in 2012 [7] and in Italy in 2018. However, 
Fig. 1. Maps showing the estimated incidence of all cancers of infectious origin (A), of HBV/HCV-related cancers (B), of HPV-related cancers 
(C), and of Hp-related cancers (D) in the male and female population of the 20 Italian regions in 2018. The incidence is drawn with a continu-
ous tonal gradation, ranging on a scale between a minimum of 3 and a maximum of 67. The number of new cases/100,000 is reported in 
each region.
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there are sharp differences in the overall contribution of 
the above agents to the incident cancers of infectious 
origin, which in the world and in Italy was 14.8% and 
6.8%, respectively. In particular, Hp, HBV + HCV, and 
HPV were responsible on a global scale for the 5.4, 4.8, 
and 5.0% of all incident cancer cases [7], whereas in 
Italy they were responsible for the 3.2, 2.3, and 1.3% of 
cases, respectively. Another important difference is that 
the total numbers of infection-related cancers world-
wide was equal in males and females, i.e. 1,100,000 
cases each in 2012 [7], whereas in Italy there were in 
2018 many more cases in males (16,000) than in females 
(11,000). This is likely to be ascribed to the fact that the 
most pronounced difference between the world and the 
Italian situation is related to HPV-related cancers, which 
displayed a female/male ratio of 3.2 in Italy and of 8.6 in 
the world [7]. Such a difference reflects the fact that in 
Italy there is a broad application both of primary preven-
tion measures (anti-HPV vaccination) and of secondary 
prevention by means of oncological screenings (PAP test 
and HPV-DNA test).
There were evident variations in cancer incidence be-
tween the North, Centre and South of Italy and among 
the 20 regions, with some characteristic clusters of 
cancers according to the geographical localization. 
Thus, there was a general trend to a North to South 
downward gradient for all cancers of infectious ori-
gin, and especially to a lower incidence in Southern 
Italy. As to HBV/HCV-related liver cancer cancers, the 
maximum incidence was detected in Northwestern re-
gions, at least in males, and the lowest incidence was 
in Central Italy. It should be noted that sub-regional 
variations may also occur. For instance, within the 
Campania region in 1998-2002 the incidences of liver 
cancer recorded by the Naples CR in the male and fe-
male populations were 34.8 and 10.2 cases/100,000 
residents, respectively, whereas the corresponding 
values recorded in the nearby Salerno CR were 14.6 
and 6.2 cases/100,000 residents, respectively [32, 33]. 
A moderate North to South downward gradient oc-
curred in the incidence of HPV-related cancers. The 
incidence of Hp-related cancers was remarkably high 
in Central Italy regions, which confirms the observa-
tion that gained the definition of “gastric cancer belt” 
in Central Italian regions [34].
A statistically significant correlation (r = 0.893, 
P  <  0.001) was detected between the estimated 2018 
incidence data of HBV/HCV and Hp-related cancers 
in the male and female population of Northern, Central 
and Southern Italy, as detected in the present study, and 
the corresponding mortality data for liver and stomach 
cancers for the period 2010-2014, standardized on the 
European population [19]. It is exceedingly difficult to 
relate cancer incidence to the incidence of the related in-
fections in each region, also because these cancers have 
a long latency time, and the information about the geo-
graphical distribution of the corresponding infections in 
the past is scanty. Furthermore, many of these infections 
are not clinically apparent and therefore they are just 
detectable by implementing ad hoc designed screening 
programs. For instance, HPV may be harbored in a la-
tent state for 20 years or longer before manifesting as 
a precancerous lesion of the cervix [35], and the latent 
period between infection with hepatotropic viruses 
and primary hepatocellular carcinoma is in the order 
of decades [36].
Assessing the incidence of infection-related cancers 
has two intrinsic limitations. The first critical point is 
that we had to extrapolate incidence data to the whole 
population. The second one is that, for each infection-
related cancer, AFs may vary depending on the region-
al area and may not necessarily be uniform over the 
whole national territory, depending on several local 
variables. 
Conclusions 
In conclusion, our estimates suggest that cancers of in-
fectious origin contributed to the overall burden of can-
cer in Italy with more than 27,000 new cases, which 
represent the 7.3% of all incident cancer cases in 2018. 
This figure is comparable to the fraction of new cancer 
cases diagnosed in Europe in 2012 that was ascribed to 
infections, which accounted for the 7.2% of all cancer 
cases [7]. 
There were differences highlighting a higher incidence 
of these cancers in males, with the exception of HPV-
related cancers. Regional variations and geographical 
clusters of cancer cases were evident, depending on 
the type of cancer and on the gender. Nevertheless, 
the overall figures were rather similar, the infection-
related cancers accounting for the 7.2, 7.6, and 7.1% 
of all cancers in Northern, Central, and Southern Italy, 
respectively. 
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Tab. S1. Estimated incidence (new cases/100,000 residents) of cancers attributable to infectious agents in Northern Italy regions in 2018.
Gender Emilia
Romagna
Friuli 
Venezia
Giulia
Liguria Lombardia Piemonte Trentino 
Alto
Adige
Valle
d’Aosta
Veneto All 
Northern
regions
Resident 
population
as to January 
2018 
M 2,162,684 589,785 743,755 4,907,685 2,123,610 525,523 61,695 2,395,801 13,510,538
F 2,289,945 625,753 813,226 5,128,573 2,252,255 542,125 64,507 2,509,236 14,225,620
M+F 4,452,629 1,215,538 1,556,981 10,036,258 4,375,865 1,067,648 126,202 4,905,037 27,746,158
Population 
covered 
by Cancer 
Registries (%)
M+F 80 100 55 92 30 100 100 53 71
Cancer site 
(ICD-10) 
Infectious 
agent
Non-cardia 
stomach 
(C16.1-C16.9)
Hp
M 30.6 35.8 25.9 28.2 27.1 19.7 26.0 20.2 26.7
F 19.6 17.8 14.3 15.1 14.0 13.0 12.4 10.9 14.6
M+F 50.3 53.6 40.2 43.3 41.1 32.7 38.4 31.1 41.3
MALT (C88.4) Hp
M 0.4 0.0 0.4 0.5 0.4 1.1 0.0 0.4 0.4
F 0.5 0.0 0.3 0.3 0.2 0.3 0.0 0.2 0.2
M+F 0.9 0.0 0.7 0.8 0.6 1.4 0.0 0.6 0.6
Total Hp-
associated 
cancers
Hp
M 31.0 35.8 26.3 28.6 27.5 20.8 26.0 20.6 27.1
F 20.1 17.8 14.6 15.3 14.2 13.2 12.4 11.1 14.9
M+F 51.1 53.6 40.9 43.9 41.7 34.0 38.4 31.7 42.0
Liver (C22)
HBV 
(± HDV) 
+ HCV
M 18.8 22.5 24.0 24.5 24.6 20.8 29.8 22.3 23.4
F 7.8 7.5 10.1 9.5 9.3 4.9 5.3 7.8 7.8
M+F 26.6 30.0 34.1 34.0 33.9 25.7 35.1 30.1 31.2
Uterine cervix
(C53)
HPV
M - - - - - - - - -
F 7.6 9.1 10.7 8.7 9.4 5.5 9.3 7.5 8.5
M+F 7.6 9.1 10.7 8.7 9.4 5.5 9.3 7.5 8.5
Vulva
(C51)
HPV
M - - - - - - - - -
F 1.2 1.4 1.1 1.0 1.0 0.8 0.8 1.1 1.0
M+F 1.2 1.4 1.1 1.0 1.0 0.8 0.8 1.1 1.0
Vagina
(C52)
HPV
M - - - - - - - - -
F 0.7 0.8 0.8 0.7 0.7 1.0 0.0 0.7 0.7
M+F 0.7 0.8 0.8 0.7 0.7 1.0 0.0 0.7 0.7
Penis
(C60)
HPV
M 0.8 0.8 1.3 0.8 1.0 0.7 0.8 0.8 0.9
F - - - - - - - - -
M+F 0.8 0.8 1.3 0.8 1.0 0.7 0.8 0.8 0.9
Oral cavity
(C00-C08)
HPV
M 0.4 0.6 0.4 0.4 0.5 0.5 0.5 0.5 0.5
F 0.3 0.3 0.3 0.2 0.3 0.2 0.3 0.3 0.3
M+F 0.7 0.9 0.7 0.6 0.7 0.7 0.8 0.8 0.8
Oropharynx
(C09-C10, 
C12-C14)
HPV
M 1.4 3.2 1.6 1.7 1.8 2.4 2.0 1.6 1.9
F 0.4 0.8 0.4 0.5 0.4 0.4 0.7 0.4 0.5
M+F 1.8 4.0 2.0 2.2 2.2 2.8 2.7 2.0 2.4
Larynx
(C32)
HPV
M 0.6 1.0 0.8 0.7 0.7 0.5 1.1 0.8 0.8
F 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1
M+F 0.7 1.1 0.9 0.8 0.8 0.6 1.3 0.9 0.9
Total HPV-
associated 
cancers
HPV
M 3.3 5.6 4.2 3.6 3.9 4.0 4.3 3.6 4.1
F 10.2 12.5 13.5 11.1 11.9 8.1 11.3 10.0 11.1
M+F 13.5 18.1 17.7 14.7 15.8 12.2 15.6 13.6 15.2
Nasopharynx
(C11)
EBV 
(HHV4)
M 1.2 0.5 1.2 1.2 1.3 0.8 1.3 0.8 1.0
F 0.4 0.5 0.4 0.4 0.4 0.4 0.0 0.4 0.4
M+F 1.6 1.0 1.6 1.6 1.7 1.2 1.3 1.2 1.4
Burkitt’s 
lymphoma
(C83.7)
EBV 
(HHV4) 
± Pf
M 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1
F 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0
M+F 0.1 0.2 0.1 0.1 0.2 0.0 0.0 0.1 0.1
Hodgkin’s 
lymphoma
(C81)
EBV 
(HHV4)
M 1.6 1.3 1.8 1.4 1.4 1.2 0.0 1.6 1.3
F 1.1 1.2 0.8 1.2 1.2 1.0 0.6 1.4 1.1
M+F 2.7 2.5 2.6 2.6 2.6 2.2 0.6 3.0 2.4
Total EBV-
associated 
cancers
EBV 
M 2.9 2.0 3.1 2.8 2.8 1.9 1.3 2.5 2.4
F 1.5 1.8 1.2 1.6 1.6 1.4 0.6 1.8 1.4
M+F 4.4 3.8 4.3 4.4 4.4 3.3 1.9 4.3 3.8
Kaposi’s 
sarcoma
(C46)
KSHV 
(HHV8)
M 2.2 1.4 1.6 2.2 2.6 1.0 1.6 1.3 1.7
F 0.8 0.0 1.1 0.8 0.9 0.6 0.0 0.2 0.6
M+F 3.0 1.4 2.7 3.0 3.5 1.6 1.6 1.5 2.3
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Adult T cell 
lymphoma/
leukemia 
(C91.5)
HTLV1
M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
M+F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
All the above 
cancers
M 58.2 67.1 59.0 61.6 61.4 48.5 63.0 50.2 58.7 
F 40.4 39.6 30.3 38.3 37.9 28.3 29.5 31.0 35.7
M+F 98.6 106.7 89.3 99.9 99.3 76.8 92.5 81.2 94.4
Hp: Helicobacter pylori; HBV: hepatitis B virus; HCV: hepatitis C virus; HDV: hepatitis D virus (Delta agent); HPV: human papillomavirus; EBV: Epstein-Barr virus; HHV4: 
human herpesvirus 4; PF: Plasmodium falciparum; KSKV: Kaposi’s sarcoma virus; HHV8: human herpesvirus 8; HTLV: human T-lymphotropic virus; M: males; F: females.
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Tab. SII. Estimated incidence (new cases/100,000 residents) of cancers attributable to infectious agents in Central Italy regions in 2018.
Gender Lazio Marche Toscana Umbria All Central
regions
Resident population
as to January 2018
M 2,848,727 743,645 1,803,203 425,547 5,821,122
F 3, 047,966 788,108 1,933,765 459,093 6,228,932
M+F 5,896,693 1,531,753 3,736,968 884,640 12,050,054
Population covered by
Cancer Registries (%)
M+F 15 0 33 100 25
Cancer site
(ICD-10)
Infectious agent
Non-cardia stomach (C16.1-C16.9) Hp
M 24.0 34.1 34.3 37.2 32.4
F 14.4 20.9 20.9 21.9 19.6
M+F 38.4 55.0 55.2 59.1 52.0
MALT (C88.4) Hp
M 0.4 0.6 0.6 0.5 0.6
F 0.3 0.4 0.3 0.3 0.3
M+F 0.7 1.0 0.9 0.8 0.9
Total Hp-associated cancers Hp
M 24.4 34.7 34.9 37.8 33.0
F 14.7 21.3 21.3 22.2 19.9
M+F 39.1 56.0 56.2 60.0 52,9
Liver (C22) HBV (± HDV) +HCV
M 18.8 16.4 15.1 18.4 17.2
F 7.9 6.9 6.4 7.6 7.2
M+F 26.7 23.3 21.5 26.0 24.4
Uterine cervix (C53) HPV
M - - - -
F 7.6 8.1 8.8 8.7 8.3
M+F 7.6 8.1 8.8 8.7 8.3
Vulva (C51) HPV
M - - - -
F 1.0 1.2 1.1 1.3 1.2
M+F 1.0 1.2 1.1 1.3 1.2
Vagina (C52) HPV
M - - - -
F 0.6 0.6 0.5 0.7 0.6
M+F 0.6 0.6 0.5 0.7 0.6
Penis (C60) HPV
M 0.9 1.2 1.1 1.3 1.1
F - - - -
M+F 0.9 1.2 1.1 1.3 1.1
Oral cavity (C00-C08) HPV
M 0.4 0.4 0.4 0.5 0.4
F 0.2 0.2 0.2 0.2 0.2
M+F 0.6 0.6 0.6 0.7 0.6
Oropharynx (C09-C10, C12-C14) HPV
M 1.2 0.9 1.0 0.9 1.0
F 0.3 0.2 0.2 0.3 0.3
M+F 1.5 1.1 1.2 1.2 1.3
Larynx (C32) HPV
M 0.7 0.6 0.7 0.6 0.7
F 0.1 0.1 0.1 0.1 0.1
M+F 0.8 0.7 0.8 0.7 0.8
Total HPV-associated cancers HPV
M 3.1 3.2 3.2 3.3 3.2
F 9.7 10.4 11.0 11.3 10.6
M+F 12.8 13.6 14.2 14.6 13.8
Nasopharynx (C11) EBV (HHV4)
M 1.2 0.9 1.0 0.8 1.0
F 0.4 0.5 0.4 0.7 0.5
M+F 1.6 1.4 1.4 1.5 1.5
Burkitt’s lymphoma (C83.7) EBV (HHV4) ± Pf
M 0.1 0.1 0.0 0.1 0.1
F 0.0 0.1 0.1 0.0 0.1
M+F 0.1 0.2 0.1 0.1 0.2
Hodgkin’s lymphoma (C81) EBV (HHV4)
M 1.6 1.8 1.9 1.7 1.7
F 1.2 1.2 1.0 1.4 1.2
M+F 2.8 3.0 2.9 3.1 2.9
Total EBV-associated cancers EBV
M 2.8 2.7 2.9 2.5 2.7
F 1.5 1.8 1.4 2.2 1.7
M+F 4.31 4.5 4.3 4.7 4.4
Kaposi’s sarcoma (C46) KSHV (HHV8)
M 2.0 1.1 1.6 0.7 1.3
F 0.8 0.3 0.2 0.2 0.4
M+F 2.8 1.4 1.8 0.9 1.7
Adult T cell lymphoma/leukemia 
(C91.5)
HTLV1
M 0.0 0.1 0.2 0.2 0.1
F 0.0 0.0 0.1 0.0 0.0
M+F 0.0 0.1 0.3 0.2 0.1
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All the above cancers
M 51.3 58.2 57.8 62.8 57.5
F 34.6 40.6 40.4 43.4 39.7
M+F 85.9 98.8 98.2 106.2 97.2
Hp: Helicobacter pylori; HBV: hepatitis B virus; HCV: hepatitis C virus; HDV: hepatitis D virus (Delta agent); HPV: human papillomavirus; EBV: Epstein-Barr virus; HHV4: 
human herpesvirus 4; PF: Plasmodium falciparum; KSKV: Kaposi’s sarcoma virus; HHV8: human herpesvirus 8; HTLV: human T-lymphotropic virus; M: males; F: females.
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Tab. SIII. Estimated incidence (new cases/100,000 residents) of cancers attributable to infectious agents in Southern Italy regions in 2018.
Gender Abruzzo Basilicata Calabria Campania Molise Puglia Sardegna Sicilia All 
Southern
regions
Resident 
population
as to January 2018
M 641,185 278,882 959,437 2,841,049 152,228 1,967,751 810,072 2,445,343 10,095,947
F 674,011 288,236 997,250 2,985,811 156,265 838,104 2,581,646 10,601,814
M+F 1,315,196 567,118 1,956,687 5,826,860 308,493 4,048,242 1,648,176 5,026,929 20,697,761
Population covered 
by
Cancer Registries 
(%)
M+F 0 100 64 71 0 54 42 91 65
Cancer site
(ICD-10)
Infectious 
agent
Non-cardia 
stomach 
(C16.1-C16.9)
Hp
M 20.0 30.0 24.4 19.9 20.5 17.6 17.8 16.1 20.8
F 13.1 17.9 12.5 12.8 13.7 11.9 11.8 10.2 13.0
M+F 33.1 47.9 36.9 32.7 34.2 29.5 29.6 26.3 33.8
MALT (C88.4) Hp
M 04 0.00 0.2 0.3 0.5 0.5 0.7 0.3 0.4
F 0.2 0.5 0.4 0.2 0.0 0.3 0.4 0.2 0.3
M+F 0.6 0.5 0.6 0.5 0.5 0.8 1.1 0.5 0.7
Total Hp-associated 
cancers
Hp
M 20.3 30.0 24.6 20.2 21.0 18.1 18.5 16.4≤ 21.1
F 13.3 18.4 12.9 13.0 13.7 12.1 12.1 10.3 13.2
M+F 33.6 48.4 37.5 33.2 34.7 30.2 30.6 26.7 34.3
Liver (C22)
HBV (± 
HDV) + 
HCV
M 20.8 21.5 20.4 22.2 21.0 19.4 22.5 14.3 20.3
F 10.7 9.9 10.1 10.8 11.3 9.2 10.7 7.5 10.0
M+F 31.5 31.4 30.5 33.0 32.3 28.6 33.2 21.8 30.3
Uterine cervix (C53) HPV
M - - - - - - - - -
F 7.1 8.0 7.4 6.8 7.0 6.9 7.0 6.9 7.1
M+F 7.1 7.98 7.42 6.80 7.04 6.87 7.04 6.86 7.14
Vulva (C51) HPV
M - - - - - - - - -
F 1.0 0.9 1.1 0.9 1.1 1.1 0.8 0.9 1.0
M+F 1.0 0.9 1.1 0.9 1.1 1.1 0.8 0.9 1.0
Vagina (C52) HPV
M - - - - - - - -
F 0.5 0.3 0.2 0.5 0.5 0.5 0.4 0.3 0.4
M+F 0.5 0.3 0.2 0.5 0.5 0.5 0.4 0.3 0.4
Penis (C60) HPV
M 1.2 0.7 1.2 1.0 1.3 1.0 1.0 1.1 1.1
F - - - - - - - - -
M+F 1.2 0.7 1.2 1.0 1.3 1.0 1.0 1.1 1.1
Oral cavity 
(C00-C08)
HPV
M 0.4 0.5 0.3 0.3 0.4 0.4 0.5 0.4 0.4
F 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2
M+F 0.6 0.6 0.5 0.5 0.6 0.6 0.6 0.6 0.6
Oropharynx
(C09-C10. C12-C14)
HPV
M 0.8 1.3 0.4 0.8 0.8 0.8 1.8 0.6 0.9
F 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2
M+F 1.00 1.4 0.6 1.0 1.0 1.0 2.0 0.8 1.01
Larynx (C32) HPV
M 0.8 0.5 0.7 0.8 0.8 0.6 0.8 0.6 0.7
F 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1
M+F 0.9 0.5 0.8 0.9 0.9 0.7 0.9 0.7 0.8
Total HPV-
associated cancers
HPV
M 3.2 3.0 2.6 2.9 3.3 2.8 4.1 2.6 3.0
F 9.0 9.3 9.1 8.6 9.1 8.9 8.7 8.4 8.9
M+F 12.2 12.3 11.7 11.5 12.4 11.7 12.8 11.0 11.9
Nasopharynx (C11) EBV (HHV4)
M 1.6 2.3 1.5 1.2 1.6 1.3 1.2 2.0 1.6
F 0.5 0.6 0.2 0.4 0.5 0.4 0.3 0.6 0.4
M+F 2.1 2.9 1.7 1.6 2.1 1.7 1.5 2.6 2.0
Burkitt’s lymphoma
(C83.7)
EBV (HHV4) 
± Pf
M 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1
F 0.00 0.0 0.00 0.0 0.0 0.0 0.0 0.0 0.0
M+F 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1
Hodgkin’s 
lymphoma (C81)
EBV (HHV4)
M 1.4 1.0 1.4 1.5 1.4 1.3 1.6 1.5 1.4
F 1.1 1.6 1.6 1.2 1.2 1.3 1.3 1.0 1.3
M+F 2.5 2.6 3.0 2.7 2.6 2.6 2.9 2.5 2.7
Total EBV-
associated cancers
EBV 
M 3.1 3.4 3.0 2.7 3.0 2.8 2.9 3.5 3.0
F 1.5 2.2 1.8 1.6 1.7 1.7 1.6 1.6 1.7
M+F 4.6 5.6 4.8 4.3 4.7 4.5 4.5 5.1 4.7
Kaposi’s sarcoma
(C46)
KSHV 
(HHV8)
M 3.0 3.6 3.0 2.4 2.6 4.3 3.2 2.0 3.0
F 1.3 1.0 0.8 1.1 1.3 2.2 1.4 0.7 1.2
M+F 4.3 4.6 3.8 3.5 3.9 6.4 4.6 2.7 4.2
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Adult T cell 
lymphoma/
leukemia (C91.5)
HTLV1
M 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
M+F 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
All the above 
cancers
M 50.3 61.4 53.5 50.3 50.8 47.4 51.4 38.8 50.5
F 35.9 40.9 34.6 35.0 37.0 34.0 34.6 28.5 35.1
M+F 86.2 102.3 88.1 85.4 87.8 81.4 86.0 67.3 85.6
Hp: Helicobacter pylori; HBV: hepatitis B virus; HCV: hepatitis C virus; HDV: hepatitis D virus (Delta agent); HPV: human papillomavirus; EBV: Epstein-Barr virus; HHV4: 
human herpesvirus 4; Pf: Plasmodium falciparum; KSKV: Kaposi’s sarcoma virus; HHV8: human herpesvirus 8; HTLV: human T-lymphotropic virus; M: males; F: females.
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Tab. SIV. Estimates of total incident cancer cases and proportion of incident cancer cases attributable to the main cancer-associated infections 
in Italian regions in 2018. 
Region Gender Total incident casesa Infection-related casesb
Northern Italy
Emilia Romagna
M 15,550 1,270 (8.2%)
F 15,350 943 (6.1%)
Friuli Venezia Giulia
M 4,750 399 (8.4%)
F 4,300 253 (5.9%)
Liguria
M 6,150 441 (7.2%)
F 5,800 336 (5.8%)
Lombardia
M 33,550 3,050 (9.1%)
F 30,650 2,001 (6.5%)
Piemonte
M 16,300 1,216 (8.1%)
F 14,550 870 (6.0%)
Trentino Alto Adige
M 3,100 257 (8.3%)
F 2,800 156 (5.6%)
Valle d’Aosta
M 450 40 (8.9%)
F 350 20 (5.7%)
Veneto
M 16,759 1,215 (7.3%)
F 15,100 789 (5.2%)
All Northern regions
M 96,600 7,987 (8.3%)
F 88,900 5,369 (6.0%)
Central Italy
Lazio
M 17,150 1,472 (8.6%)
F 16,700 1,074 (6.4%)
Marche
M 5,000 437 (8.7%)
F 4,800 325 (6.8%)
Toscana
M 12,900 1,053 (8.2%)
F 12,000 796 (6.6%)
Umbria
M 3,050 270 (8.9%)
F 2,900 202 (7.0%)
All Central regions
M 38,100 3,233 (8.5%)
F 36,400 2,397 (6.6%)
Southern Italy and Islands
Abruzzo
M 4,200 324 (7.7%)
F 3,800 245 (6.4%)
Basilicata
M 1,850 174 (9.4%)
F 1,400 118 (8.4%)
Calabria
M 5,850 514 (8.8%)
F 4,500 346 (7.7%)
Campania
M 16,350 1,420 (8.7%)
F 13,700 1,056 (7.7%)
Molise
M 1,000 77 (7.7%)
F 900 59 (6.6%)
Puglia
M 10,850 936 (7.9%)
F 10,750 716 (6.7%)
Sardegna
M 5,200 417 (8.0%)
F 4,800 292 (6.1%)
Sicilia
M 13,900 956 (6.9%)
F 13,250 746 (5.6%)
All Southern Italy and Islands
M 60,200 4,418 (8.0%)
F 53,100 3,577 (6.7%)
All Italian regions
M 194,900 16,038 (8.2%)
F 178,400 11,223 (6.4%)
M+F 373,300 27,381 (7.3%)
a From AIOM/AIRTUM [19]. b From Tables SI-SIII.
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Fig. S1. Geographical distribution of the 20 Italian regions.
